Lucerno Dynamics asset deal gives Radnostix new route into nuclear medicine workflows
Discover how Radnostix’s Lucerno Dynamics deal could reshape radiopharmaceutical monitoring, dosimetry and theranostics delivery.
Can LIFT and NorthStar move Lu-177-LT17 into the next radioligand therapy frontier?
Find out how LIFT and NorthStar’s Lu-177-LT17 partnership could advance radioligand therapy for cancer bone disease today!
Novartis bets on Texas as radioligand therapy moves closer to mainstream oncology
RLT demand is rising faster than supply chains can stretch. Novartis’ Texas buildout tests whether precision oncology can scale.